| Literature DB >> 23685020 |
Jatinder Goyal1, Gregory R Pond2, Matthew D Galsky3, Ryan Hendricks3, Alexander Small3, Che-Kai Tsao3, Guru Sonpavde4.
Abstract
OBJECTIVES: The independent prognostic effect of comorbidities on outcomes in men with metastatic castration-resistant prostate cancer (mCRPC) is unclear. We sought to determine whether the Charlson comorbidity index (CCI) and hypertension (HTN) are associated with overall survival (OS) independent of known clinical prognostic factors in mCRPC. PATIENTS AND METHODS: A retrospective analysis was conducted on 221 patients with mCRPC treated with docetaxel plus prednisone combined with AT-101 (bcl-2 antagonist) or placebo on a prospective randomized phase II trial. The Cox regression analysis was performed to identify whether the CCI or HTN or both (by medical history) independently predicted OS after adjusting for baseline variables known to be associated with OS. The Wilcoxon rank sum test and the Fisher exact test were used to compare data by comorbidity groups (CCI as a continuous variable, CCI = 6 vs. CCI ≥ 7 and HTN vs. no HTN).Entities:
Keywords: Charlson comorbidity index; Docetaxel; Hypertension; Metastatic castration-resistant prostate cancer; Overall survival; Progression-free survival
Mesh:
Substances:
Year: 2013 PMID: 23685020 DOI: 10.1016/j.urolonc.2013.02.015
Source DB: PubMed Journal: Urol Oncol ISSN: 1078-1439 Impact factor: 3.498